Axogen, Inc.
AXGNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeAxogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. Valued at $2.51B, AXGN is a mid-cap name in its sector. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Market Cap
$2.51B
Beta
1.16
P/E (TTM)
—
P/E (Fwd)
67.30
EPS (TTM)
$-0.67
EPS (Fwd)
$0.69
ROE
-18.2%
ROA
-3.1%
Cash
$111.4M
Total Debt
$20.1M
Free CF
$18.2M
52W Change
200.4%
Annual Financials
Cash vs Debt
Where AXGN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, AXGN finished 22.19% above its 150-day moving average ($39.53) and 29.49% above its 200-day moving average ($37.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AXGN overbought or oversold?
At the September 3, 2026 close, AXGN's RSI(14) was 50.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Axogen, Inc. holds $111.4M in cash against $20.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $18.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -18.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $127.4M (2021) to $225.2M (2025), reflecting a 77% increase over the period.
With cash comfortably exceeding debt, AXGN has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AXGN.